Karen Aboody received her MD at Mount Sinai School of Medicine, and completed her post-doctoral training in Molecular Neurogenetics at Massachusetts General Hospital, Harvard Medical School. She currently heads a translational stem cell-oncology laboratory at City of Hope, focused on using tumor-tropic stem cells as delivery vehicles to target therapeutic agents to invasive and metastatic solid tumors, including brain tumors. In 2010, she received FDA approval for a first-in-human clinical safety trial for neural stem cell (NSC)-mediated enzyme/prodrug therapy for patients with recurrent high-grade glioma. She also received an $18MM CIRM Disease Team Award in 2010 to bring a second generation NSC-mediated therapeutic product to clinical trial for brain tumors by 2014. Recently, she received an NIH U-01 to translate this NSC-mediated approach for the treatment of metastatic neuroblastoma. Dr. Aboody received the AANS Young Investigator award in 2000, and the ASGT Outstanding New Investigator Award in 2008. In 2011, she founded TheraBiologics Inc., a clinical stage biopharmaceutical company, to support clinical development of NSC-mediated cancer therapies.
Neural Stem Cell Mediated Cancer Therapy: From Bench to Phase I Brain Tumor Trial
Monday, 22 April 2013 at 11:00
Add to Calendar ▼2013-04-22 11:00:002013-04-22 12:00:00Europe/LondonNeural Stem Cell Mediated Cancer Therapy: From Bench to Phase I Brain Tumor TrialClinical Translation of Stem Cells Summit in Palm Springs, CA, USAPalm Springs, CA, USASELECTBIOenquiries@selectbiosciences.com
Human neural stem cells (NSCs) are inherently tumor--tropic, localizing to tumor foci following intracerebral or intravenous administration in preclinical models of brain tumors, breast carcinoma, and neuroblastoma. These NSCs can be engineered to express numerous therapeutic agents, making them an attractive drug delivery vehicle. Here, we highlight the pre--clinical characterization, safety and therapeutic efficacy study results that led to permission from the U.S. Food and Drug Administration to initiate a first--in--human phase I study using genetically modified NSCs for tumor selective enzyme/prodrug therapy in recurrent glioma patients (clinicaltrials.gov ID # NCT01172964).
Add to Calendar ▼2013-04-22 00:00:002013-04-23 00:00:00Europe/LondonClinical Translation of Stem Cells SummitClinical Translation of Stem Cells Summit in Palm Springs, CA, USAPalm Springs, CA, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2013-04-22 11:00:002013-04-22 12:00:00Europe/LondonNeural Stem Cell Mediated Cancer Therapy: From Bench to Phase I Brain Tumor TrialClinical Translation of Stem Cells Summit in Palm Springs, CA, USAPalm Springs, CA, USASELECTBIOenquiries@selectbiosciences.com
